ReviewCurrent neurology and neuroscience reports2014
Neuromyelitis optica spectrum disorders.
Review in Current neurology and neuroscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Neuromyelitis optica spectrum disorder overlapping with Sjögren's disease: immunopathological links and therapeutic implications.Frontiers in immunology · 2026Review
- [Classic presentation of neuromyelitis optica: clinical case and review of the literature].Revista medica del Instituto Mexicano del Seguro Social · 2024Review
- It Looks Like a Spinal Cord Tumor but It Is Not.Cancers · 2024Review
- ACT001 Relieves NMOSD Symptoms by Reducing Astrocyte Damage with an Autoimmune Antibody.Molecules (Basel, Switzerland) · 2023Article
- Neuroimaging features in inflammatory myelopathies: A review.Frontiers in neurology · 2022Review
- Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings.Radiology case reports · 2021Article
- Epidemiology of neuromyelitis optica spectrum disorder in Denmark (1998-2008, 2007-2014).Brain and behavior · 2019Review
- Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.The American journal of case reports · 2018Article
- Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.Annals of neurology · 2016Article
- An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.Therapeutic advances in neurological disorders · 2016Review
- Circulating Memory T Follicular Helper Cells in Patients with Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorders.Mediators of inflammation · 2016Article
- A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis.Current neurology and neuroscience reports · 2015Review
- Follicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal Models.Mediators of inflammation · 2015Review
- Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been recognized as being associated with this condition. This observation has led to new proposed terminology for the entire disorder, NMO spectrum disorders (NMOSD). The discovery of a pathogenic autoantibody and its target antigen has also facilitated basic research into the immunopathogenesis of the disease. Key advances include establishment of passive transfer animal models demonstrating the pathogenic potential of the autoantibody and confirming an important role of complement suggested by immunopathology of NMO brain lesions and of B-cell subsets, plasmablasts in particular. These discoveries have led to phase 1 clinical trials of targeted immunotherapy with potential for improved efficacy and less toxicity than current empiric immunosuppressant medications used to treat NMOSD. Randomized clinical trials are beginning to assess the efficacy and safety of a variety of immunotherapies in NMOSD. Therapeutic options are likely to increase, and improved outcomes in NMOSD patients are anticipated.
Indexed as
Identifiers
25027264What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.